Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2007

01-04-2007 | Therapy In Practice

Optimal Management Strategies for Chronic Iron Overload

Author: Dr James C. Barton

Published in: Drugs | Issue 5/2007

Login to get access

Abstract

Iron overload is characterised by excessive iron deposition and consequent injury and dysfunction of target organs, especially the heart, liver, anterior pituitary, pancreas and joints. Iron overload disorders are common worldwide and occur in most major race/ethnicity groups. Physiological mechanisms to excrete iron are very limited. Thus, all patients with iron overload need safe and effective treatment that is compatible with their co-existing medical conditions. Treatments for iron overload include phlebotomy and erythrocytapheresis that remove iron predominantly as haemoglobin, and chelation therapy with drugs that bind excess iron selectively and increase its excretion. The most important potential benefits of therapy are preventing deaths due to cardiac siderosis and hepatic cirrhosis. Preventing iron-related injury to endocrine organs is critical in children. Successful treatment or prevention of iron overload increases quality of life and survival in many patients. This article characterises the major categories of iron overload disorders, tabulates methods to evaluate and treat iron overload, and describes treatment options for iron overload disorders. Research needed to advance knowledge about treatment of iron overload is proposed.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
2.
Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001, 47–61
3.
Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319–24PubMedCrossRef
4.
Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408PubMedCrossRef
5.
Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program 2003, 40–61
6.
Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa: interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95–100PubMedCrossRef
7.
Barton JC, Acton RT, Rivers CA, et al. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis 2003; 31: 310–9PubMedCrossRef
8.
Beutler E, Barton JC, Felitti VJ, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305–9PubMedCrossRef
9.
Jaeger M, Aul C, Sohngen D, et al. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes [in German]. Beitr Infusionsther 1992; 30: 464–8PubMed
10.
Gattermann N. Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators. Hematol Oncol Clin 2005; 19 Suppl. 1: 13–7
11.
Vassiliadis T, Garipidou V, Perifanis V, et al. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006; 12: 818–21PubMed
12.
Halpern Z, Rahmani R, Levo Y. Severe hemochromatosis: the predominant clinical manifestation of congenital dyserythropoietic anemia type 2. Acta Haematol 1985; 74: 178–80PubMedCrossRef
13.
Bett JH, Wilkinson RK, Boyle CM. Iron overload associated with congenital pyruvate kinase deficiency and high dose ascorbic acid ingestion [letter]. Aust N Z J Med 1985; 15: 270PubMedCrossRef
14.
Barton JC, Lee PL, West C, et al. Iron overload and prolonged ingestion of iron supplements: Clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol 2006; 81: 760–7PubMedCrossRef
15.
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567–73PubMedCrossRef
16.
Ceci A, Baiardi P, Cataprano M, et al. Risk factors for death in patients with β-thalassemia major: results of a case-control study. Haematologica 2006; 91: 1420–1PubMed
17.
Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005; 1054: 40–7PubMedCrossRef
18.
Witte DL, Crosby WH, Edwards CQ, et al. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200CrossRef
19.
Wu KH, Tsai FJ, Peng CT. Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment. Ann Hematol 2003; 82: 637–40PubMedCrossRef
20.
De Sanctis V, Roos M, Gasser T, et al. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab 2006; 19: 471–80PubMed
21.
Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9PubMed
22.
Carneiro AA, Vilela GR, Fernandes JB, et al. In vivo tissue characterization using magnetic techniques [abstract]. Neurol Clin Neurophysiol 2004; 2004: 85PubMed
23.
Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration? Blood 2006; 108: 1775–6PubMedCrossRef
24.
Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15–9PubMedCrossRef
25.
Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106: 1460–5PubMedCrossRef
26.
Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol 2005; 123: 146–52PubMedCrossRef
27.
St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855–61CrossRef
28.
Kellner H, Zoller WG. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol 1992; 30: 779–83PubMed
29.
de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med 1979; 300: 5–8PubMedCrossRef
30.
Kaltwasser JP, Werner E, Schalk K, et al. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998; 43: 699–704PubMedCrossRef
31.
Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994; 83: 2329–33PubMed
32.
Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood 1982; 60: 288–94PubMed
33.
Hershko C, Link G, Konijn AM. Chelation therapy in iron overload. In: Barton JC, Edwards CQ, editors. Hemochromatosis: genetics, pathophysiology, diagnosis and treatment. Cambridge: Cambridge University Press, 2000: 339–54CrossRef
34.
35.
Araujo A, Kosaryan M, MacDowell A, et al. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br J Haematol 1996; 93: 835–7PubMedCrossRef
36.
Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997; 130: 86–8PubMedCrossRef
37.
Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol 2002; 509: 91–125PubMedCrossRef
38.
Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516–20PubMedCrossRef
39.
Liu DY, Liu ZD, Hider RC. Oral iron chelators: development and application. Best Pract Res Clin Haematol 2002; 15: 369–84PubMed
40.
Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995; 86: 2008–13PubMed
41.
Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122: 305–10PubMedCrossRef
42.
Agarwal MB, Gupte SS, Vasandani D, et al. Efficacy and safety of 1–2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload. J Assoc Physicians India 1991; 39: 669–72PubMed
43.
Kontoghiorghes GJ, Aldouri MA, Sheppard L, et al. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987; I: 1294–5CrossRef
44.
Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995; 332: 918–22PubMedCrossRef
45.
al Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995; 89: 403–8CrossRef
46.
Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583–7PubMedCrossRef
47.
Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330–6PubMedCrossRef
48.
Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339: 417–23PubMedCrossRef
49.
Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100: 1566–9PubMedCrossRef
50.
Barton JC. Deferasirox Novartis. Curr Opin Investig Drugs 2005; 6: 327–35PubMed
51.
Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005; 18: 289–98PubMedCrossRef
52.
Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565–72PubMed
53.
Piga A, Galanello R, Foschini ML, et al. Once-daily treatment with the oral iron chelator ICL670 (Exjade): results of a phase II study in pediatric patients with beta-thalassemia major. Blood 2004, 104
54.
Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873–80PubMed
55.
Porter J, Vichinsky E, Rose C, et al. A phase II study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload [abstract]. Blood 2004; 104: 872a
56.
Vanorden HE, Hagemann TM. Deferasirox: an oral agent for chronic iron overload. Ann Pharmacother 2006; 40: 1110–7PubMedCrossRef
57.
Glickstein H, El RB, Shvartsman M, et al. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005; 106: 3242–50PubMedCrossRef
58.
Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006; 108: 3195–203PubMedCrossRef
59.
Piga A, Galanello R, Cappelini MD, et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy [abstract]. Blood 2002; 100: 5a
60.
Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597–602PubMedCrossRef
61.
Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455–62PubMedCrossRef
62.
Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976; 45: 611–23PubMed
63.
McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003; 325: 53–62PubMedCrossRef
64.
Bolan CD, Conry-Cantilena C, Mason G, et al. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001; 41: 819–27PubMedCrossRef
65.
Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003; 98: 2072–7PubMedCrossRef
66.
Conte D, Mandelli C, Cesana M, et al. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis: report of 14 cases. Int J Artif Organs 1989; 12: 59–62PubMed
67.
Fraquelli M, Mandelli C, Cesarini L, et al. Survival and development of neoplasms in 56 patients with idiopathic hemochromatosis [in Italian]. Ann Ital Med Int 1992; 7: 26–9PubMed
68.
Kohan A, Niborski R, Daruich J, et al. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2000; 79: 40–5PubMedCrossRef
69.
Mariani R, Pelucchi S, Perseghin P, et al. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005; 90: 717–8PubMed
70.
Cesana M, Mandelli C, Tiribelli C, et al. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine. Am J Gastroenterol 1989; 84: 150–2PubMed
71.
Fabio G, Minonzio F, Delbini P, et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by severe type of juvenile hemochromatosis (JH). Blood 2007; 109: 362–4PubMedCrossRef
72.
Wohler F. The treatment of haemochromatosis with desferrioxamine. Acta Haematol 1963; 30: 65–87CrossRef
73.
Speight AN, Cliff J. Iron storage disease of the liver in Dar es Salaam: a preliminary report on venesection therapy. East Afr Med J 1974; 51: 895–902PubMed
74.
Kattamis A, Papassotiriou I, Palaiologou D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006; 91: 809–12PubMed
75.
Efthimiadis GK, Hassapopoulou HP, Tsikaderis DD, et al. Survival in thalassaemia major patients. Circ J 2006; 70: 1037–42PubMedCrossRef
76.
Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8: 543–7PubMedCrossRef
77.
Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733–7PubMedCrossRef
78.
Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124: 114–7PubMedCrossRef
79.
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171–9PubMedCrossRef
80.
Anderson LJ, Westwood MA, Prescott E, et al. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 2006; 115: 106–8PubMedCrossRef
81.
Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84: 113–7PubMedCrossRef
82.
Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574–8PubMedCrossRef
83.
Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051–2PubMedCrossRef
84.
Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489–96PubMed
85.
Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28: 196–208PubMedCrossRef
86.
Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738–44PubMedCrossRef
87.
Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17–24PubMedCrossRef
88.
Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121: 938–48PubMedCrossRef
89.
Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361–4PubMedCrossRef
90.
Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90: 1309–14PubMed
91.
D’Angelo E, Mirra N, Rocca A, et al. Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia. J Pediatr Hematol Oncol 2004; 26: 451–3PubMedCrossRef
92.
Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30: 239–49
93.
Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91: 1241–3PubMed
94.
Wu KH, Chang JS, Tsai CH, et al. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004; 83: 471–3PubMedCrossRef
95.
Tavecchia L, Masera N, Russo P, et al. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica 2006; 91: ECR19PubMed
96.
Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus: trends and risk factors over the period 1980–2004. Haematologica 2006; 91: 1187–92PubMed
97.
Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992; 79: 2741–8PubMed
98.
Kearney SL, Nemeth E, Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007; 48: 57–63PubMedCrossRef
99.
Barton JC, Lee PL, Bertoli LF, et al. Iron overload in an African American woman with SS hemoglobinopathy and a promoter mutation in the X-linked erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Blood Cells Mol Dis 2005; 34: 226–8PubMedCrossRef
100.
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91: 288–94PubMed
101.
Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5–11PubMedCrossRef
102.
Adams RJ, Brambilla DJ, Granger S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004; 103: 3689–94PubMedCrossRef
103.
Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006; 108: 847–52PubMedCrossRef
104.
Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81: 858–63PubMedCrossRef
105.
Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38: 30–6PubMedCrossRef
106.
Adams DM, Schultz WH, Ware RE, et al. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol 1996; 18: 46–50PubMedCrossRef
107.
Hartwig D, Schlager F, Bucsky P, et al. Successful long-term erythrocytapheresis therapy in a patient with symptomatic sickle-cell disease using an arterio-venous fistula. Transfus Med 2002; 12: 75–7PubMedCrossRef
108.
Hilliard LM, Williams BF, Lounsbury AE, et al. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 1998; 59: 28–35PubMedCrossRef
109.
Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83: 1136–42PubMed
110.
Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 1999; 14: 122–5PubMedCrossRef
111.
Raj AB, Condurache T, Bertolone S, et al. Quantitative assessment of ventricular function in sickle cell disease: effect of long-term erythrocytapheresis. Pediatr Blood Cancer 2005; 45: 976–81PubMedCrossRef
112.
Cohen A, Schwartz E. Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr 1978; 92: 659–62PubMedCrossRef
113.
Pippard MJ. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematol 1987; 78: 206–11PubMedCrossRef
114.
Treadwell MJ, Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin Hematol 2001; 38: 77–84PubMedCrossRef
115.
Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer 2005; 44: 500–7PubMedCrossRef
116.
Shalev O, Hileti D, Nortey P, et al. Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol 1999; 105: 1081–3PubMedCrossRef
117.
Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005; 84: 434–40PubMedCrossRef
118.
Okpala I. Investigational agents for sickle cell disease. Expert Opin Investig Drugs 2006; 15: 833–42PubMedCrossRef
119.
Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743–5PubMedCrossRef
120.
121.
Bowen D. What is ineffective erythropoiesis in myelodysplastic syndromes? Leuk Lymphoma 1995; 18: 243–7PubMedCrossRef
122.
Rose C, Cambier N, Mahieu M, et al. Iron overload and myelodysplastic syndromes [in French]. Transfus Clin Biol 2001; 8: 422–32PubMedCrossRef
123.
Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–603PubMedCrossRef
124.
Barton JC, Bertoli LF, Acton RT. HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer 2004; 4: 6PubMedCrossRef
125.
Varkonyi J, Tarkovacs G, Karadi I, et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 2003; 109: 64–7PubMedCrossRef
126.
Hannuksela J, Savolainen ER, Koistinen P, et al. Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders. Haematologica 2002; 87: 131–5PubMed
127.
Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4: 58–77PubMed
128.
Borgna-Pignatti C, Franchini M, Gandini G, et al. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica 1998; 83: 788–90PubMed
129.
Del Rio GJ, Fernandez LC, Batlle Fonrodona FJ. Desferrioxamine in the treatment of myelodysplastic syndromes. Haematologica 1997; 82: 639–40
130.
Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288–99PubMedCrossRef
131.
Jiang Y, Xue ZH, Shen WZ, et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 2005; 19: 1239–47PubMedCrossRef
132.
Leardi A, Caraglia M, Selleri C, et al. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol 1998; 102: 746–52PubMedCrossRef
133.
Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992; 80: 121–4PubMedCrossRef
134.
Marsh JH, Hundert M, Schulman P. Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 1990; 76: 148–9PubMedCrossRef
135.
Meo A, Ruggeri A, La Rosa MA, et al. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin 2006; 30: 131–7PubMedCrossRef
136.
Cermak J. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. Hemoglobin 2006; 30: 105–12PubMedCrossRef
137.
Kersten MJ, Lange R, Smeets ME, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996; 73: 247–52PubMedCrossRef
138.
al Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol 1994; 53: 298–301CrossRef
139.
Gattermann N, Cazzola M, Greenberg P, et al. The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndromes (MDS) and iron overload. Leuk Res 2005; 29 Suppl. 1: S76
140.
Angelucci E, Muretto P, Lucarelli G, et al. Treatment of iron overload in the ‘ex-thalassemic’: report from the phlebotomy program. Ann N Y Acad Sci 1998; 850: 288–93PubMedCrossRef
141.
Barton JC, Lee PL. Disparate phenotypic expression of ALAS2 R452H (nt 1407 G → A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells Mol Dis 2006; 36: 342–6PubMedCrossRef
142.
Caines AE, Kpodonu J, Massad MG, et al. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant 2005; 24: 486–8PubMedCrossRef
143.
Barton JC, Edwards CQ, Bertoli LF, et al. Iron overload in African Americans. Am J Med 1995; 99: 616–23PubMedCrossRef
144.
Hoffbrand AV, Bartlett AN, Veys PA, et al. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial [letter]. Lancet 1989; II: 457CrossRef
145.
Alter BP. Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation [letter]. Lancet 1990; 335: 970PubMedCrossRef
146.
Kontoghiorghes GJ, Bartlett AN, Sheppard L, et al. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. Arzneimittelforschung 1995; 45: 65–9PubMed
147.
Donovan JM, Plone M, Dagher R, et al. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci 2005; 1054: 492–4PubMedCrossRef
148.
Hider RC, Zhou T. The design of orally active iron chelators. Ann N Y Acad Sci 2005; 1054: 141–54PubMedCrossRef
149.
Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions: comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin 2006; 30: 329–47PubMedCrossRef
Metadata
Title
Optimal Management Strategies for Chronic Iron Overload
Author
Dr James C. Barton
Publication date
01-04-2007
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2007
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200767050-00004

Other articles of this Issue 5/2007

Drugs 5/2007 Go to the issue

Adis Drug Profile

Sitaxentan

Adis Drug Evaluation

Imatinib

Review Article

Pharmacological Neuroprotection for Glaucoma

Adis Drug Evaluation

Zoledronic Acid

Current Opinion

Drospirenone for Oral Contraception and Hormone Replacement Therapy

Leading Article

Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia